An international coalition to combat the shortage of cancer drugs in poor countries

<div id="firstBodyDiv" data-bind-html-content-type="article" data-bind-html-compile="article.body" data-first-article-body="

Currently, less than 50% of the cancer drugs Listed World Health Organization of essential medicines in low- and middle-income countries, and as the disease becomes more prevalent, three out of every four cancer deaths are expected to occur in these countries over the next decade.

In the first tangible step of the Alliance (Access Oncology), Novartis licensed the drug nilotinib used in blood cancer treatment to the United Nations Medicines Patent Pool to allow manufacturers of generic drugs, with the same formulation as forfeited drugs, to produce it on a large scale and at a lower cost.

The coalition said it had previously shared the technology used to make HIV drugs and covid-19 In this way, however, nilotinib is the first non-communicable disease drug given to the compound.

The International Union Against Cancer, an important partner of the coalition, stated that the coalition does not seek to provide pharmaceutical Not only, but also training support and diagnostic methods, as quoted "Reuters".

The alliance will start with $32 million from the private sector and will initially focus on capacity building activities in ten low- and middle-income countries and the development of existing initiatives.

“>

Currently, less than 50% of the cancer drugs Listed World Health Organization of essential medicines in low- and middle-income countries, and as the disease becomes more prevalent, three out of every four cancer deaths are expected to occur in these countries over the next decade.

In the first tangible step of the Alliance (Access Oncology), Novartis licensed the drug nilotinib used in blood cancer treatment to the United Nations Medicines Patent Pool to allow manufacturers of generic drugs, with the same formulation as forfeited drugs, to produce it on a large scale and at a lower cost.

The coalition said it had previously shared the technology used to make HIV drugs and covid-19 In this way, however, nilotinib is the first non-communicable disease drug given to the compound.

The International Union Against Cancer, an important partner of the coalition, stated that the coalition does not seek to provide pharmaceutical Not only, but also support training and diagnostic methods, according to “Reuters”.

The alliance will start with $32 million from the private sector and will initially focus on capacity building activities in ten low- and middle-income countries and the development of existing initiatives.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.